Compare VCEL & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCEL | IMCR |
|---|---|---|
| Founded | 1989 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1996 | 2016 |
| Metric | VCEL | IMCR |
|---|---|---|
| Price | $32.55 | $31.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $58.50 | ★ $64.70 |
| AVG Volume (30 Days) | ★ 416.0K | 349.8K |
| Earning Date | 05-18-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | 30.39 |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $276,259,000.00 | $249,428,000.00 |
| Revenue This Year | $19.09 | $14.39 |
| Revenue Next Year | $17.96 | $8.19 |
| P/E Ratio | $102.78 | ★ N/A |
| Revenue Growth | 16.45 | ★ 43.05 |
| 52 Week Low | $29.24 | $23.15 |
| 52 Week High | $48.75 | $40.71 |
| Indicator | VCEL | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 32.81 | 44.14 |
| Support Level | $31.34 | $31.21 |
| Resistance Level | $38.48 | $34.86 |
| Average True Range (ATR) | 1.37 | 1.68 |
| MACD | -0.38 | 0.02 |
| Stochastic Oscillator | 3.78 | 29.38 |
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.